2021年4月1日,中国双特异性抗体药物龙头康方生物-B(9926.HK)发布2020年业绩报告,亮点颇多。过去一个年度,康方生物共有1项新药上市申请获得受理,4个注册性临床研究达到主要终点,3项临床试验处于注册性阶段;截止2020年底,康方生物共有40余项临床试验在全球同步开展,其中9项为注册性/III期临床试验,22项临床试验进入Ib/II期阶段。此外,康方生物在2020年还获得了2个FDA/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.